CHICAGO, July 16 (Reuters) - An experimental Alzheimer's disease drug developed by Acumen Pharmaceuticals (ABOS.O), opens new tab targeting a novel form of the toxic protein beta amyloid in the brain ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results